Autoinjectors Market Size: USD 6.21 Billion by 2033, Amid Steady 18.23% CAGR Growth

Autoinjectors Market Overview:

According to Straits Research, the global autoinjectors market size was estimated at USD 1.62 billion in 2023 and is projected to grow from USD 1.88 billion in 2024 to USD 6.21 billion by 2032, exhibiting a CAGR of 18.23% during the forecast period (2024-2032).

Autoinjectors are used to administer a drug's recommended dose without needing a personalized medical practitioner. The devices are less prone to inducing allergic reactions in the body, which makes them a popular choice in patients who show allergic reactions during drug administration. The injections or drug-injecting devices cause an anaphylaxis reaction that may be life-threatening. In October 2017, the U.S FDA approved Bydureon BCise (exenatide extended-release) auto-injectable suspension for treating type 2 diabetes in adults. According to the American Diabetes Association, around 30.3 million people in America were suffering from diabetes, and approximately 1.25 million Americans were children in 2015.

Download the Sample Pages of this Report for Better Understanding @ https://straitsresearch.com/report/autoinjector-market/request-sample

Autoinjectors Market Drivers

Patient Preference for Self-Injections: Increasing inclination among patients to self-administer injections rather than rely on clinical or hospital settings. The desire for autonomy, fewer hospital visits, and more convenience are pushing demand.

Rising Demand for Biosimilars and Patent Expiry of Biologics: As biologic drugs' patents expire, biosimilar versions become available, often making drug and device combinations more affordable. This drives more usage and encourages device innovation to accommodate biosimilars.

Increasing Prevalence of Chronic and Autoimmune Diseases: Diseases such as rheumatoid arthritis, diabetes, multiple sclerosis, asthma, and allergic conditions requiring emergency medication are on the rise globally, increasing the need for regular injections.

Home Care and Remote/Outpatient Settings: There is a growing trend toward shifting healthcare away from hospitals to home care and self-care settings. Patients prefer devices that facilitate treatment at home, especially aging populations who may have limited mobility or access to healthcare facilities.

Autoinjectors Market Segmentation

Based on therapy, the autoinjectors market is segmented into anaphylaxis, rheumatoid arthritis, psoriasis, migraine, cardiovascular disease, and other emergency conditions. Anaphylaxis reaction is expected to lead the market during the forecast period 2024-2032.

Based on type, the market is segmented into disposable and reusable. Disposable autoinjectors are expected to hold a major market share. Today, the demand for disposable autoinjectors is rapidly growing to prevent the spread of contagious diseases like AIDS, TB, and blood-borne infections. According to the World Health Organisation, around 36.9 million people worldwide had HIV/AIDS in 2017, and the number has grown substantially in the last two years. On the other hand, the prevalence of diabetes is growing at an exponential rate. As per the WHO, over 422 million people across the globe have diabetes, which further drives the demand for reusable auto injectors.

On the basis of the end-users, the global autoinjectors market is segmented into hospitals & clinics and home care and diagnostic centers. Home care is likely to lead the market in the years to come.

Get Detailed Market Segmentation @ https://straitsresearch.com/report/autoinjector-market/segmentation

Competitive Players

Eli Lilly
Scandinavian Health Ltd.
AbbVie, Inc.
Amgen
Owen Mumford
Ypsomed
Teva Pharmaceutical
Biogen Idec
Mylan N.V.
Pfizer, Inc.
Sanofi
West Pharmaceutical Services, Inc.
Recipharm AB
Viatris Inc.
BD

To Visit Here For Grab More Insights @ https://straitsresearch.com/report/autoinjector-market

Regional Analysis

Geographically, the global autoinjectors market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (LAMEA).

Asia Pacific is expected to grow at the highest CAGR, owing to increased sensitivity towards allergens, rising prevalence of cardiac, orthopedic, and skin diseases, such as psoriasis. The study suggested that Japan and Korea are the major consumers of autoinjectors in the region. Recently, Enbrel launched autoinjectors in Japan, which can be used in infections, including tuberculosis or infections caused by bacteria, viruses, or fungi.

According to the World Health Organization, Tuberculosis killed over 2800 people, and the rate of incidence was 0.085% in 2017. Out of them, 77% were diagnosed with pulmonary, and 9% were diagnosed with HIV and TB. In 2016, incidence and mortality rates of tuberculosis in the Republic of Korea were 77 and 55.2 per 100,000 people, Economic Cooperation and Development. In Korea, more than 28,161 and 36,044 new TB cases were diagnosed in 2016 and 2017, respectively. This increasing number of tuberculosis patients is likely to fuel the demand for autoinjectors in the Asia Pacific Region.

North America is expected to dominate the global autoinjectors market during the forecast period, owing to the increasing prevalence of foodborne illness and cardiovascular diseases like hypertension, stroke, and cardiac arrest. Europe is expected to hold the second-largest market share during the forecast period on account of the increasing number of people having hypersensitivities. On the other hand, LAMEA is expected to witness sluggish growth due to slow adoption of technology and fewer research and development activities in the drug administration process. As per the World Health Organisation, 26% and 37% of deaths were reported due to cardiovascular diseases in Brazil and Saudi Arabia in 2016, respectively.

Inquiry Before Buying @ https://straitsresearch.com/buy-now/autoinjector-market

Contact Us:

Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com

About Us:

StraitsResearch.com is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.

This release was published on openPR.